RCUS
Arcus Biosciences (NYSE: RCUS) announced that its management team will host a conference call and webcast...
Article Summary
HOLD- Arcus Biosciences (NYSE: RCUS) announced that its management team will host a conference call and webcast on August 5, 2026 to discuss details of financial results and pipeline updates for the quarter ended June 30th 2026, with Arcus Biosciences focused on developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases.
- Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer.
- The company is expediting development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel biology-driven combinations that have the potential to help people with cancer live longer.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 67.4% | 25% | 100.0 ptsExceptional (67.4%) - Hypergrowth |
| EPS Growth Next 5Y ? | 11.1% | 25% | 35.0 ptsBelow Screener (11.1%) - Modest outlook |
| Target Price Upside ? | 28.6% | 20% | 75.0 ptsSignificant Upside (28.6%) - Target: $37.91 vs Current: $29.48 |
| Gross Margin % ? | 96.2% | 15% | 100.0 ptsExceptional (96.2%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -7.1% | 15% | 20.0 ptsBarely a Dip (-7.1%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About RCUS
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
- The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
- It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
- In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer.
- It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer.
- Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.